Nippon Kayaku To Start Apaziquone Trials This Year
This article was originally published in PharmAsia News
Nippon Kayaku plans to start clinical study for apaziquone, an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation
You may also be interested in...
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.